Incyte Co. (NASDAQ:INCY) – Investment analysts at Gabelli increased their FY2020 earnings per share estimates for Incyte in a report issued on Wednesday. Gabelli analyst J. He now forecasts that the biopharmaceutical company will earn $4.35 per share for the year, up from their previous estimate of $4.30.

Several other research firms have also weighed in on INCY. BMO Capital Markets lowered their price target on Incyte from $163.00 to $162.00 and set an “outperform” rating on the stock in a research report on Thursday, October 26th. Royal Bank of Canada lowered their price target on Incyte from $136.00 to $120.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 21st. Oppenheimer set a $135.00 price target on Incyte and gave the stock a “hold” rating in a research report on Tuesday, October 31st. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Incyte in a research report on Tuesday, October 31st. Finally, Deutsche Bank initiated coverage on Incyte in a research report on Tuesday, December 12th. They set a “hold” rating and a $106.00 price target on the stock. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $143.71.

Incyte (NASDAQ:INCY) opened at $93.16 on Friday. The firm has a market capitalization of $19,660.00, a P/E ratio of -116.45 and a beta of 0.74. Incyte has a 1 year low of $88.81 and a 1 year high of $153.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.11. The firm had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business’s quarterly revenue was up 41.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 EPS.

In related news, insider David W. Gryska sold 3,915 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vijay K. Iyengar sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total value of $486,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 44,878 shares of company stock valued at $4,636,494 over the last quarter. 17.70% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INCY. Riverhead Capital Management LLC boosted its stake in Incyte by 22.0% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,030 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 546 shares during the period. Seven Eight Capital LP bought a new stake in Incyte in the 2nd quarter valued at $129,000. Ameriprise Financial Inc. boosted its stake in Incyte by 6.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 228,079 shares of the biopharmaceutical company’s stock valued at $28,722,000 after purchasing an additional 13,564 shares during the period. PNC Financial Services Group Inc. boosted its stake in Incyte by 17.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 36,123 shares of the biopharmaceutical company’s stock valued at $4,549,000 after purchasing an additional 5,284 shares during the period. Finally, Rafferty Asset Management LLC boosted its stake in Incyte by 55.8% in the 2nd quarter. Rafferty Asset Management LLC now owns 12,111 shares of the biopharmaceutical company’s stock valued at $1,525,000 after purchasing an additional 4,340 shares during the period. Institutional investors and hedge funds own 90.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “FY2020 Earnings Estimate for Incyte Co. Issued By Gabelli (INCY)” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/01/21/fy2020-earnings-estimate-for-incyte-co-issued-by-gabelli-incy.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.